Halozyme Therapeutics, Inc.
NASDAQ: HALO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Helen I. Torley
- Employees
- 350
- Headquarters
- San Diego, United States
- IPO year
- 2004
- Market cap
- $8.1B
- Website
- https://www.halozyme.com
Loading HALO…
Loading profile data…Frequently asked questions about HALO
What does Halozyme Therapeutics, Inc. (HALO) do?
Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHANZE drug delivery platform, which utilizes a patented recombinant human hyaluronidase enzyme (rHuP...
Where does HALO trade?
Halozyme Therapeutics, Inc. (HALO) trades on the NASDAQ Global Select.
What sector is HALO in?
Halozyme Therapeutics, Inc. (HALO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Halozyme Therapeutics, Inc.?
Helen I. Torley is the chief executive officer of Halozyme Therapeutics, Inc. (HALO).
Where is Halozyme Therapeutics, Inc. headquartered?
Halozyme Therapeutics, Inc. is headquartered in United States.
Does HALO pay a dividend?
Halozyme Therapeutics, Inc. (HALO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did HALO go public?
Halozyme Therapeutics, Inc. (HALO) completed its initial public offering in 2004.